4C Medical Technologies has announced that its medical device therapy for mitral regurgitation was featured in the Innovation Summit at Cardiovascular Innovations (CVI) 2017 (2 August, Denver, USA). A press release reports that the company developing the first mitral regurgitation therapy that preserves the native mitral valve and left ventricle using a supra-annular, atrial-only fixation technology.
According to the press release, the novel design eliminates known issues of current transcatheter mitral valve implantation (TMVI) technologies that rely on placement and fixation in the native mitral annulus and left ventricle.
Philippe Généreux (Hôpital du Sacré-Coeur de Montréal, Montreal, Canada) says: “The mitral valve anatomy is complex, with many different mitral regurgitation mechanisms. Current TMVI devices have experienced challenges trying to imitate surgical procedures. It is very exciting to see 4C Medical’s innovative approach—positioning the implant in the left atrium above the native annulus, with no presence in the left ventricle—to simplify mitral regurgitation treatment and provide a therapeutic option to a broader patient population.”
4C Medical recently reported that it exceeded its US$8 million convertible note offering goal, raising approximately US$9 million that will be used to finalise the design of the technology and conduct the early feasibility study.
